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ABSTRACT: The dystonias are a group of
hyperkinetic movement disorders whose principal cause
is neuron dysfunction at 1 or more interconnected
nodes of the motor system. The study of genes and
proteins that cause familial dystonia provides critical in-
formation about the cellular pathways involved in this
dysfunction, which disrupts the motor pathways at the
systems level. In recent years study of the increasing
number of DYT genes has implicated a number of cell
functions that appear to be involved in the pathogene-
sis of dystonia. A review of the literature published in
English-language publications available on PubMed
relating to the genetics and cellular pathology of dysto-
nia was performed. Numerous potential pathogenetic
mechanisms have been identified. We describe those
that fall into 3 emerging thematic groups: cell-cycle and
transcriptional regulation in the nucleus, endoplasmic
reticulum and nuclear envelope function, and control of
synaptic function. VC 2013 Movement Disorder Society
Key Words: DYT genes; cell cycle; endoplasmic
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The dystonias are a heterogeneous group of hyperki-
netic movement disorders characterized by sustained
involuntary muscle spasms and postures.1 The most
common forms are primary, in which dystonic move-
ments are the only clinical feature and there is no evi-
dence of neurodegeneration. In the majority of these
cases, the cellular processes that lead to functional
abnormalities of neurons, sufficient to disrupt the
finely tuned control of movement, are unknown.
However, in recent years the identification of genes
that cause rare monogenic familial dystonia has given
insight into the neurobiology of dystonia and shed
light on the molecular mechanisms involved. Further
evidence has come from the study of more complex
forms of secondary dystonia, in which there is evi-
dence of neurodegeneration or central nervous system
(CNS) damage and the dystonic movements are part
of a more complex neurological phenotype.
The purpose of this review is to summarize the evi-
dence, predominantly from the study of genetic forms
of dystonia, and highlight cellular pathways that are
important to the genesis of dystonia. In particular, it
focuses on areas where there are common themes to
the cellular pathogenesis. Most of this information
comes from study of monogenic primary dystonias
and the proteins that the various DYT genes encode.
The genetic classification of dystonia has subtypes
DYT 1–25 and includes pure primary dystonias, dys-
tonia-plus syndromes, in which other features such as
myoclonus or parkinsonism are present, and paroxys-
mal dyskinesias, in which dystonia is often a promi-
nent feature. Table 1 describes the DYT loci,
showing key clinical features and information about
the protein encoded by the DYT gene. The following
sections describe the specific forms of primary and
dystonia-plus syndromes for which the gene and pro-
tein have been identified and studied and that are dis-
cussed in this review.
DYT1 Dystonia: TorsinA
DYT1 dystonia is caused by a heterozygous 3-bp
GAG deletion in the TOR1A gene.2 TorsinA is a 332–
amino acid protein typical of the AAA1 (ATPases
associated with a variety of cellular activities) protein
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TABLE 1. Summary of genes and proteins involved in genetic forms of primary dystonia and dystonia-plus syndromes
Locus Designation Clinical features Gene/inheritance Protein Putative functions
Pure dystonia
DYT1 Chr9q34.11 Early-onset primary
dystonia
Childhood onset dys-
tonia in limb with
generalization
TOR1A Autosomal
dominant
TorsinA AAA1 protein, nuclear
envelope, ER secre-
tory and stress
response, regulation
of synaptic function
DYT2 Early-onset dystonia Adolescent-onset seg-
mental or
generalized
Autosomal recessive Unknown
DYT4 Chr19p13.3 Whispering dysphonia Childhood-onset laryn-
geal abductor
spasm with cervical
dystonia
TUBB4a Autosomal
dominant
Beta-tubulin 4a Structural cytoskeleton
protein
DYT6 Chr 8p11.21 AD early-onset focal
dystonia
Early-onset dystonia
with prominent cer-
vical and laryngeal
involvement
THAP1 Autosomal
dominant
Thanatos-associated
domain-containing
apoptosis associ-
ated protein 1
Atypical zinc-finger
protein; THAP do-
main is chromatin-
binding factor and
regulates
transcription
DYT7 Chr 8p Familial focal dystonia Adult-onset focal
dystonia
Unknown Autosomal
dominant
Unknown
DYT13 Chr1p36.32-
p36.13
Familial craniocervical
dystonia
Focal or segmental
dystonia of cranio-
cervical region and
upper limbs
Unknown Autosomal
dominant
Unknown
DYT17 Chr 20p11.2-
2q13.12
Early-onset AR
dystonia
Early-onset focal dys-
tonia progressing to
generalized with
dysphonia and
dysarthria
Unknown Autosomal
recessive
Unknown
DYT21 Chr 2q14.3-
q21.3
Late-onset dystonia Late-onset multifocal
and generalized
dystonia
Unknown Autosomal
dominant
Unknown
DYT23 Chr9q34.11 Cervical dystonia Late-onset primary
cervical dystonia
CIZ1 Autosomal
dominant
Cip1-interacting zinc
finger protein 1
Regulation of G1-S
cell cycle and DNA
replication
DYT24 Chr11p14.2 Late-onset dystonia Cranial and cervical
dystonia
ANO3 Autosomal
dominant
Anoctamin 3 Calcium-gated chlo-
ride channel
DYT25 Chr18p Cervical dystonia with
local spread
Predominantly late-
onset primary cervi-
cal dystonia with
spread to face
GNAL Autosomal
dominant
Alpha subunit of G
protein
Probable interaction
with D1 and adeno-
sine 2A receptors.
Dystonia plus syndromes
DYT3 Xq13.1 X-linked dystonia
(Lubag)
Segmental or general-
ized dystonia with
parkinsonism
TAF1 X-linked TATA box-binding pro-
tein associated fac-
tor 1
Regulation of tran-
scription initiation
and cell cycle
DYT5/14 Chr2q13.2 Dopa-responsive
dystonia
Dystonia with parkin-
sonism, diurnal var-
iation, very good
response to L-dopa
GCH1 Autosomal
dominant
GTP cyclohydrolase 1 Rate-limiting enzyme
in synthesis of tet-
rahydrobiopterin,
key cofactor in
monoamine synthe-
sis; results in defi-
cient dopamine
synthesis
DYT11 Chr7q21.3 Myoclonic dystonia
syndrome
Upper body myoclonic
jerks with dystonia;
responsive to
alcohol
SGCE Autosomal
dominant
Epsilon-sarcoglycan Cell membrane protein
that may act as
structural platform
for other protein
interactions
DYT12 Chr19q13.2 Rapid onset dystonia
parkinsonism
Acute-onset general-
ized dystonia with
parkinsonism, ros-
trocaudal gradient
of symptoms
ATP1A3 Autosomal
dominant
Alpha 3 subunit of
Na/K ATPase
Subunit of Na/K
ATPase on neuronal
membrane
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family; these proteins typically function as oligomers
and use the energy of ATP hydrolysis for many func-
tions including protein trafficking, membrane fusion,
protein refolding, and degradation.3 The pathogenic
codon deletion (DE) in torsinA removes a glutamic acid
residue from a C-terminal alpha helix believed to be
critical for oligomerization and/or tertiary structure.4
TorsinA is ubiquitously expressed in numerous cell
types including neurons and glia within the CNS.5–8
TorsinA mRNA is expressed in sensorimotor regions of
the brain including the cerebral cortex, striatum, sub-
stantia nigra pars compacta, thalamus, hippocampus,
midbrain, pons, cerebellum, and spinal cord.5–8 It has
been suggested that the neuron-specific effect of mutant
torsinA occurs, as there is low expression of other
forms of torsin, notably torsinB, and cannot therefore
correct for the presence of dysfunctional torsinA.9
DYT4 Dystonia: Beta-Tubulin 4a
Study of a large family with autosomal dominant whis-
pering dysphonia and generalized dystonia revealed a
single cosegregating mutation in the beta-tubulin 4a
gene.10 The mutation in the beta-tubulin autoregulatory
domain was highly expressed in the nervous system and
implicates the cytoskeleton in dystonia pathogenesis.
DYT6 Dystonia: THAP1
Dystonia-causing mutations in THAP1 (Thanatos-
associated protein domain containing apoptosis
associated protein 1) have been widely reported.11,12
THAP1 is a transcription factor and a member of
THAP protein family that contains an evolutionarily
conserved zinc-dependent DNA-binding domain.
Mutations in THAP1 include several reported dele-
tions and nonsense mutations, including one that
removes the start codon. Many of the mutations occur
in the DNA-binding domain and several appear to dis-
rupt the nuclear localization signal.13–15 In addition,
at least 1 mutation appears to cause disease through
recessive inheritance.16 Considered together, these
observations suggest that THAP1 may cause dystonia
through a loss-of-function mechanism.
Before its identification as a dystonia-causing gene,
THAP1 was reported to regulate cell proliferation via
regulation of pRB/E2F cell-cycle target genes, and
another report pointed to a potential proapoptotic
role related to localization in promyelocytic leukemia
nuclear bodies.17,18
DYT11 Myoclonus Dystonia:
Epsilon-Sarcoglycan
Epsilon-sarcoglycan (SGCE) is a member of the sar-
coglycan protein family that comprises plasma trans-
membrane proteins. Most SGCE mutations are
deletions or nonsense mutations that eliminate gene
function.19 The SGCE gene is maternally imprinted,
meaning that individuals are dependent on expression
from the paternal allele. Nearly all myoclonus-
TABLE 1. Continued
Locus Designation Clinical features Gene/inheritance Protein Putative functions
DYT15 Chr 18p11 Myoclonus dystonia Childhood-onset myo-
clonus with variable
dystonia
Unknown Autosomal
dominant
Unknown
DYT16 Chr2q31.2 DRD and
parkinsonism
Dystonia-parkinsonism
with bulbar involve-
ment and
bradykinesia
PRKRA Autosomal
recessive
Protein kinase, inter-
feron-inducible dou-
ble-stranded RNA
dependent activator
PRKRA is activator of
proteins involved in
response to cell
stress
Paroxysmal dystonia
DYT8 Chr2q35 Paroxysmal nonkinesi-
genic dyskinesia
(PKND)
Attacks of dystonia or
choreoathetosis.
Precipitants: stress,
alcohol, fatigue,
coffee
MR-1 Autosomal
dominant
Myofibrillo-genesis
regulator 1
Affect neuronal stress
response pathways
DYT9 and DYT18
Chr1p34.2
Paroxysmal exercise
induced dystonia
Episodic ataxia
Dystonia (usually limb)
brought on by exer-
cise; ataxia/spastic-
ity between attacks
GLUT1 Autosomal
dominant
Glucose transporter
type 1
Reduced glucose
transport to neu-
rons with unstable
metabolic state
DYT10 and DYT19
Chr16p11.2
Proxysmal kinesigenic
choreoathetosis
(PKC)
Attacks of dystonia or
choreoathetosis
precipitated by sud-
den movement;
associated with mi-
graine and epilepsy
PRRT2 Autosomal
dominant
Proline-rich trans-
membrane protein
2
Interacts with SNAP25
and may affect
synaptic functions/
neuronal excitability
DYT20 Chr 2q31 Canadian PKND PKND phenotype Unknown Autosomal
dominant
Unknown
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dystonia patients inherit a loss-of-function allele from
their father and therefore lack functional SGCE
protein.
Sarcoglycans are components of the dystrophin-gly-
coprotein complex (DGC), a membrane-spanning
complex that makes connections with the extracellular
matrix and the intracellular actin cytoskeleton.20,21
Although DGC function is typically described in stri-
ated muscle, where its dysfunction is linked to several
muscular dystrophies, DGC proteins are also
expressed in the CNS. SGCE is found in many brain
regions and is associated with dopaminergic neurons
in the substantia nigra and ventral tegmental areas.22
In neurons, DGC proteins (including SGCE) concen-
trate at postsynaptic sites and have been localized to
GABAergic inhibitory synapses.23,24 This association
with GABAergic synapses may contribute to the defi-
cient inhibition that is observed in many forms of pri-
mary dystonia.
DYT16 Dystonia-Parkinsonism: PRKRA
DYT16 is less prevalent than DYT1 and DYT6,
having been described in only a small number of fami-
lies.25 The gene encodes the protein PRKRA (protein
kinase, interferon-inducible double-stranded RNA-de-
pendent activator), also known as PACT, which regu-
lates activity of protein kinase R.26
DYT23 Dystonia: Cip1-Interacting Zinc Finger
Protein 1
A recent study has identified a Cip1-interacting zinc
finger protein 1 (CIZ1; c.790A>G, p.S264G) muta-
tion in a large white pedigree with late-onset primary
cervical dystonia.27 Screening in subjects with adult-
onset cervical dystonia identified 2 additional missense
mutations in CIZ1 (p.P47S and p.R672M).
CIZ1 encodes Cip1-interacting zinc finger protein 1,
a DNA replication factor. CIZ1 was first identified
through its interaction with p21Cip1/Waf1 (CDKN1A),
a cyclin-dependent kinase inhibitor involved in G1-S
cell-cycle regulation and cellular differentiation.27
CIZ1 is expressed in the cerebellum, cerebral cortex,
substantia nigra, and putamen of the adult human
brain.28
DYT24 Dystonia: Anoctamin 3
Exome sequencing in an autosomal dominant family
with craniocervical dystonia identified a putative
mutation in the anoctamin 3 (ANO3) gene, and addi-
tional mutations were found in other familial and spo-
radic cases of cervical dystonia.29 ANO3 is expressed
highly in the striatum, but also the neocortex, hippo-
campus, and amygdala. Anoctamin 3 is believed to act
as a calcium-gated chloride channel, and functional
studies using Ca21 imaging in case and control
fibroblasts demonstrated abnormalities in endoplasmic
reticulum–dependent Ca21 signaling.
DYT25 Dystonia: GNAL
Recently, mutations in GNAL have been identified
in 11 multiplex families (autosomal dominant) pre-
dominantly with cervical and segmental dystonia.30,31
GNAL encodes the stimulatory alpha subunit Gaolf,
first identified as a G-protein that mediates odorant
signaling in the olfactory epithelium, coupling D1 and
A2a receptors to adenylyl cyclase and histone H3
phosphorylation.
The following sections focus on mechanisms that
have been derived from the study of a number of the
studied genes described above but will also consider
pathogenesis of selected forms of secondary dystonia.
Three key areas can be identified in which there
appear to be shared molecular pathways: (1) cell cycle
and transcription, (2) nuclear envelope/endoplasmic
reticulum (ER) interface and ER secretory pathways,
and (3) synaptic function.
Defects at the G1-S Cell-Cycle Checkpoint
The eukaryotic cell cycle consists of 4 distinct
phases: gap 1 (G1), synthesis (S), gap 2 (G2), and mi-
tosis (M). In addition, terminally differentiated cells
like neurons enter a quiescent state call gap 0, or G0.
The G1 phase is commonly known as the growth
phase. During G1, cells prepare for the DNA synthesis
that will occur in the S phase. DNA is synthesized and
chromosomes are replicated during the S phase. The
G1-S cell-cycle checkpoint pathway controls the tran-
sition from the end of G1 to S. The G1-S cell-cycle
checkpoint ensures that the cell is fully prepared for
DNA synthesis. Numerous factors such as DNA dam-
age from irradiation, contact inhibition, TGFb, and
oxidative stress can inhibit transition from G1 to S,
and the G1-S checkpoint has also been implicated in
the molecular pathology of dystonia.
CIZ1
The cellular role and neural localization of CIZ1 are
compatible with current themes in dystonia research.
CIZ1, TOR1A, THAP1, and genes associated with
neurodegenerative dystonia seen in DYT3 dystonia
(TAF1) and ataxia telangiectasia (ATM) are involved
in G1-S cell-cycle regulation (Fig. 1).
In cell-free systems, CIZ1 is able to promote DNA
replication after replication complex formation.32 The
C-terminal domain anchors CIZ1 to the nonchromatin
nuclear matrix, whereas DNA replication activity
resides in the N-terminal half of the protein. The C-
terminal domain of CIZ1 also recognizes the consen-
sus DNA sequence ARYSR(0–2)YYAC.33 Studies of
GFP-tagged CIZ1 have shown that formation of
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FIG. 1. G1/S cell-cycle checkpoint and dystonia. Dystonia-associated proteins are shaded red. Indirect, multistep, and putative pathways are
denoted with hashed lines. In general, arrows indicate excitatory interactions, and stops mark inhibitory interactions. However, some relationships
are nonlinear and the result of combinatorial actions of heteromeric complexes and posttranslational modifications. 1p, Phosphorylation; ATM,
ataxia telangiectasia mutated; ATR, ataxia telangiectasia and Rad3-related protein; CDC25A, cell division cycle 25 homolog A; CDK2, cyclin-de-
pendent kinase 2; CDK4, cyclin-dependent kinase 4; CDK6, cyclin-dependent kinase 6; CDKN1A, p21/WAF1 or cyclin-dependent kinase inhibitor 1;
CHK1, checkpoint kinase 1; CIZ1, Cip1-interacting zinc finger protein; E2F, transcription factor E2F; G1 phase, gap 1 phase of the cell cycle; p53,
protein 53; R, restriction point; Rb, retinoblastoma protein; SMAD2, mothers against decapentaplegic homolog 2; SMAD3, mothers against decap-
entaplegic homolog 3; S phase, synthesis phase; TAF1, transcription initiation factor TFIID subunit 1; TFDP1, transcription factor Dp1; TGFb, trans-
forming growth factor b.
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subnuclear particles or foci requires both the N- and
C-terminal domains.34
The N-terminal region of CIZ1, including the first
zinc finger motif, binds to the N-terminal CDK2-inter-
acting domain of CDKN1A, and this interaction is dis-
rupted by overexpression of CDK2.35 When CIZ1 and
CDKN1A are individually overexpressed, they localize
primarily to the nucleus. However, overexpression of
CIZ1 can induce cytoplasmic distribution of
CDKN1A, suggesting that CIZ1 regulates the cellular
localization of CDKN1A.
In cell-free experiments, CIZ1 increases the number
of nuclei that initiate DNA replication, and in intact
wild-type and CDKN1A-null cells, CIZ1 stimulates
DNA synthesis. Consistent with a role in DNA repli-
cation, endogenous CIZ1 was found to colocalize with
proliferating cell nuclear antigen (PCNA) during S
phase, and targeted depletion of CIZ1 retrains cell
proliferation by inhibiting entry into S phase.31 CIZ1-
depleted cells accumulate chromatin-bound minichro-
mosome maintenance complex component 3 MCM3
and PCNA but fail to synthesize DNA efficiently.31
CIZ1 is an estrogen-responsive gene.36 CIZ1 coregu-
lates estrogen receptor alpha (ERa) by enhancing ERa
transactivation activity and promoting the recruitment
of the ERa complex to target genes. CIZ1 overexpres-
sion confers estrogen hypersensitivity and promotes
growth rate, anchorage independence, and tumorigenic
properties in breast cancer cells. It is tempting to spec-
ulate that aberrant interactions between ERa and
CIZ1 or other, as yet unidentified dystonia-related
proteins contribute to the relative increased prevalence
of cervical dystonia in females.
THAP1
THAP1 plays an important role in transcriptional
regulation in the context of cell proliferation and pRb/
E2F cell-cycle pathways.18,37,38 Both RNAi silencing
and overexpression of THAP1 inhibit G1-S progres-
sion. Overexpression of THAP1 in primary human en-
dothelial cells inhibited proliferation, and gene
expression profiling showed that this effect was a
result of repression of pRB/E2F cell-cycle target genes.
The antiproliferative effects of THAP1 on endothelial
cells were not dependent on apoptosis. THAP1
appears to inhibit cell-cycle progression at the G1-S
transition, localizes to promyelocytic leukemia nuclear
bodies with the proapoptotic leucine-zipper protein
Par-4, and potentiates TNFa-induced apoptosis.17
Clouaire and colleagues (2005) identified a consen-
sus DNA-binding sequence (AGTACGGGCAA) recog-
nized by the THAP domain of THAP1.39 Nucleotide
positions upstream of the core motif appear to modu-
late the strength and affinity of the GGCA/THAP
interaction. Other THAP zinc fingers, including
human THAP2 and THAP3, share structural
homology but do not recognize the same DNA target
sequence. Protein–protein interactions, including mul-
timerization, mediated by the coiled-coil domain of
THAP1 may increase binding of the THAP zinc finger.
Human THAP1, human THAP9, and Drosophila
THAP bind DNA through a bipartite interaction using
both the major and minor grooves.40
Overexpression of THAP1 in endothelial cells has
been used as an indirect means of identifying THAP1
targets.18 A total of 16 genes were upregulated >1.5-
fold, and 80 downregulated. Of the latter group, the
genes were concentrated in classes related to cell-cycle/
cell proliferation, and the majority were also regulated
by the pRB/E2F pathway. The cellular effects of
THAP1 knock-down with RNAi were similar to the
effects of overexpression. In addition, THAP1 knock-
down was associated with decreased expression of 8
pRB/E2F cell-cycle target genes: RRM1, Mad2, survi-
vin, HMMR, RRM2, CDC2, cyclin B1, and DLG7.
RRM1 was shown to be a direct transcriptional target
of THAP1. Potential THAP1 binding sites were also
identified in the promoters of other genes: RRM2,
BIRC2, survivin, and cyclin B1.
Studies have also focused on a potential functional
interaction with torsinA. THAP1 was reported to bind
to and activate the promoter of the Tor1a gene that
encodes torsinA, although these studies did not dem-
onstrate changes in torsinA mRNA following manipu-
lation of THAP1.41,42 Moreover, there do not appear
to be sequence alterations in the genes encoding
THAP1 or torsinA that explain disease penetrance in
DYT1 dystonia.43,44
Two hybrid studies have identified several protein
interactions for THAP1.17,45 Analysis of the set of
interacting proteins suggests that THAP1 may contrib-
ute to transcription, splicing, and, possibly, RNA
transport. Interestingly, several interacting proteins
indirectly implicate THAP1 in cerebellar development.
For example, NKAP is a transcriptional repressor act-
ing on Notch target genes and is required for T-cell
development. Notch 1 is required for neuronal and
glial differentiation in the cerebellum.46 FXR2, a
homologue of the fragile X mental retardation protein
(FMRP), is involved in mRNA transport. Deletion of
FMRP in mice is associated with cerebellar ultrastruc-
tural abnormalities and motor learning deficits.47
Finally, DVL2 appears to be involved in the Wnt sig-
naling pathway, which is critical for cerebellar mor-
phogenesis.48 There is an increasing body of evidence
that implicates the cerebellum in the genesis of dys-
tonic movements,49 and these data suggest that
THAP1 could lead to subtle functional abnormalities
of cerebellar functions.
Although often considered a neurodegenerative dis-
order, some patients with Lubag (DYT3) manifest iso-
lated focal (including cervical) or segmental dystonia
years before the development of parkinsonism.50
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DYT3 is associated with deficiency of a neuronal iso-
form of TAF1 (N-TAF1) that is expressed preferen-
tially in medium spiny neurons of the striosome
compartment.51,52 TAF1 (TATA box-binding protein
[TBP] associated factor 1) forms part of the TFIID
transcriptional complex that is composed of TBP and
up to 13 additional TAFs. TFIID binds to TATA
boxes and participates in transcriptional initiation.
Deficiency of defective TAF1 could exert deleterious
effects on cell-cycle control via multiple mechanisms.
For instance, TAF1 induces G1-S progression by phos-
phorylating p53 at threonine-55.53 In TAF1-defective
cell lines, ATR localizes to subnuclear foci and con-
tributes to phosphorylation of downstream targets
such as p53 and CHK1, which induces cell-cycle
arrest.54 Finally, TAF1 has been shown to undergo al-
ternative splicing in response to developmental or
DNA damage signals.55
TorsinA
TorsinA binds the KASH domain of nesprin-3,
which spans the nuclear envelope (NE) outer mem-
brane, and TA is concentrated at the nuclear envelope
in its mutant form. TorsinA appears to play a role in
interactions between the nucleus and cytoskeleton.26
These interactions may be important for cell polarity
and/or transcription.56,57 Alternatively, torsinA may
participate in transcriptional regulation and/or G1-S
cell-cycle regulation via the TGFb pathway.58,59 Dro-
sophila larvae that overexpress mutant DE torsinA ex-
hibit overt ultrastructural defects at the neuromuscular
junction similar to defects reported for mutants with
defective TGFb signaling.60,61 Overexpression of
SMAD2, a downstream effector of the TGFb path-
way, corrects morphological and behavioral defects
associated with expression of mutant torsinA.58
Variant ataxia-telangiectasia from recessive muta-
tions in ATM may present with dystonia.62 This is
similar to THAP1 dystonia, with frequent craniocervi-
cal and upper limb involvement, and can occur in the
absence of cerebellar atrophy on MRI or ataxia on
clinical examination. ATM (ataxia telangiectasia
mutated) is a serine/threonine kinase activated by
DNA double-strand breaks and can phosphorylate
p53, effector kinase CHK2, and an inhibitor of p53,
MDM2.63 CHK2 also phosphorylates p53. Activation
of p53 leads to increased expression of the Cdk inhibi-
tor p21 and contributes to maintenance of cell-cycle
arrest.
GNAL
Ga(olf) is found widely in brain with particularly ro-
bust expression in the striatum and cerebellar Purkinje
cells.31 In the striatum, Ga(olf) may contribute to cell-
cycle control via its role in phosphorylation of histone
H3.64 At the transcriptional level, mutations in GNAL
have been associated with upregulation of genes
involved in cell-cycle control and development.31
Neuronal death is an important phenomenon in the
development of the nervous system, and the above
suggests 1 or more dystonia-associated proteins
(CIZ1, THAP1, torsinA, N-TAF1, Ga[olf], and ATM)
may contribute to this process.7,12,65 For example,
cell-cycle control and the G1-S checkpoint are known
to be critical to olivocerebellar development.66 In the
cerebellar cortex, for instance, cell death may main-
tain numerical matching between granule and Purkinje
cells (175:1). The downstream consequences of mutant
or deficient dystonia-associated proteins could be aber-
rant cell-cycle reentry in terminally differentiated neu-
rons, leading to numerical mismatch between specific
neuronal populations or ultrastructural defects of spe-
cific neuronal types such Purkinje cells or medium
spiny neurons.67–70
Endoplasmic Reticulum/Nuclear
Envelope–Associated Dystonia Proteins
Another area in which there appears to be convergence
in pathogenic mechanisms in dystonia is the endoplasmic
reticular/nuclear envelope (ER/NE) endomembrane sys-
tem. Several genes that cause dystonia when mutated
encode proteins associated with the ER/NE system.
Included in this group are torsinA, epsilon-sarcoglycan,
and THAP1. The ER/NE membrane system is in the cell
interior, and critically, all proteins must pass through this
organelle to become membrane-embedded. Membrane-
embedded proteins such as ion channels and neurotrans-
mitter receptors and transporters are precisely the types
of molecules that would be expected to cause the neural
dysfunction seen in primary dystonia.
TorsinA
TorsinA resides in the ER lumen, and several obser-
vations support a role for torsinA in membrane traf-
ficking. It can inhibit trafficking of polytopic
membranebound proteins, including the dopamine
transporter, an effect suppressed by the DE muta-
tion.71 Similarly, protein processing through the secre-
tory pathway is defective in fibroblasts from patients
with DYT1 dystonia, an abnormality that is rescued
by downregulating the mutant protein.72,73 TorsinA
function in the ER also appears to affect the ability of
a neuron to withstand cellular stress. Overexpression
of torsinA protects cells from ER stress.74 Conversely
torsinA knockdown or the DE mutation sensitizes cells
to ER stress.73 These effects may relate to a role for
torsinA in endoplasmic reticular–associated degrada-
tion, a process whereby misfolded proteins are
removed from the ER lumen and degraded by the pro-
teasome.75,76 Interestingly, the DYT16 protein
PRKRA (PACT) may also play a role in regulating ER
stress via induction of protein kinase R.77
L e D O U X E T A L
974 Movement Disorders, Vol. 28, No. 7, 2013
TorsinA also functions at the nuclear envelope.78,79
A “substrate trap” version of torsinA that prevents it
from uncoupling from protein partners causes it to
accumulate abnormally in the NE.80–82 Similarly, dis-
ease mutant DE-torsinA concentrates abnormally at
the nuclear membrane, indicating that the DYT1
mutation may lead to an abnormal interaction with an
NE partner,80,83 possibly lamina-associated polypep-
tide 1 (LAP1).84 The neuronal nuclear membranes
from torsinA null of DE-homozygous knock-in mice
exhibit abnormal nuclear envelope membranes, pro-
viding in vivo evidence for an NE role for torsinA.80
Considered together, these observations suggest that
the DYT1 mutation impairs normal torsinA function.
The role of torsinA within the NE is not well under-
stood but may involve regulating connections between
proteins that tether the nucleus to the cytoskeletal net-
worker transcriptional regulation at the inner NE
membrane.78,85 These functions may intersect with
that of epsilon-sarcoglycan, a protein that participates
in nucleo-cytoskeletal connections, and the transcrip-
tion factor THAP1 (Fig. 2).
Epsilon-Sarcoglycan
The connection of epsilon-sarcoglycan (SCGE) func-
tion to the actin cytoskeleton, which itself has links to
the nuclear membrane, points to a possible connection
between torsinA and SCGE. TorsinA has been impli-
cated in regulating connections between the nucleus
and the cytoskeleton, in particular through its reported
interactions with the nesprins, a family of outer NE
proteins that themselves can interact with the actin cy-
toskeleton. TorsinA has been reported to interact with
nesprin-3, which mislocalizes in cells lacking torsinA or
that harbor DYT1 mutant torsinA.86 Several reports
have demonstrated that nesprin-3 can connect to the
actin cytoskeleton, consistent with a potential func-
tional connection between torsinA and SCGE. This
connection between torsinA and SCGE may also be in
part direct, as torsinA has been reported to interact
with and promote the degradation of SGCE mutants in
the ER.87 Abnormalities of the actin cytoskeleton could
account for observations of neural process abnormal-
ities in cell lines overexpressing torsinA.88,89
THAP1
Although THAP1 does not appear to have a direct
effect on torsinA expression, there are other ways that
nuclear-localized THAP1 could potentially interact
with torsinA-related pathways. The nuclear membrane
is increasingly recognized as a site of transcriptional
regulation through several mechanisms.90,91 It is possi-
ble that THAP1 targets are dysregulated in DYT1 dys-
tonia, in which mutant torsinA mislocalizes to the
nuclear membrane. It is also possible that THAP1 and
torsinA pathways connect via pRB, as this is a
THAP1-binding partner that also indirectly connects
to torsinA via laminA and LAP1. Direct testing of
these possibilities awaits the identification of THAP1
target genes in neurons, which can then be assessed in
DYT1 and forms of primary dystonia.
Synaptic Function
Primary dystonia and the dystonia-plus syndromes
are characterized by the absence of neurodegeneration,
implying a functional neuronal defect that leads to the
FIG. 2. Potential interactions of torsinA and THAP1 at the nuclear envelope.
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abnormal movement command. This may be a neuro-
chemical defect, possibly for multiple neurotransmitter
pathways. The hypothesis that primary dystonia is a
result of disturbance of neurotransmitters or synaptic
transmission is an attractive one, and there is evidence
to support this, particularly involving the dopaminer-
gic pathway (Fig. 3). The clearest example is from a
study of dopa-responsive dystonia in which mutations
encoding proteins critical for dopamine (DA) biosyn-
thesis, including GTP-cyclohydrolase 1 and tyrosine
hydroxylase, cause dystonia.92,93 Most cases of DRD
are due to GTPCH1 mutations; GTPCH1 is the rate-
limiting step in production of tetrahydrobiopterin,
which is a key cofactor in the synthesis of mono-
amines, particularly dopamine. Reduced levels of func-
tional GTPCH1 lead to reduced DA levels and
dystonia. DRD, therefore, responds very well to L-
dopa therapy, which corrects the presynaptic deficit of
DA.94
D2 receptor antagonists can cause tardive dysto-
nia,95 and dystonia is also seen in Parkinson’s disease,
particularly young onset,96 and Lesch–Nyhan syn-
drome, in which there is preferential loss of nigral do-
paminergic neurons.97 Furthermore, other DA-related
abnormalities have been found in various forms of
focal primary dystonia, including reduced basal gan-
glia D2 receptor binding in imaging studies and possi-
ble association of dystonia with polymorphisms in the
D5 receptor gene.98,99
TorsinA
The finding of torsinA mRNA in neurons of the sub-
stantia nigra led to neurochemical analysis of dopa-
mine and its metabolites in postmortem brain
tissue.5,100 However, these studies were inconclu-
sive.101,102 Similarly, studies in various transgenic
mouse models provided inconsistent results regarding
metabolite levels .103–106 However, more recent work
in a model using the TH promoter to drive expression
of wild-type or mutant torsinA has suggested a defect
in DA reuptake implicating the DA transporter
(DAT).107,108 This has been supported by findings of
reduced DA reuptake in hMT-CMV mice109 and a
recent study in DYT knock-in mice showing that TH-
positive substantia nigra neurons were slightly reduced
in number and increased in size,110 and evidence of a
direct interaction between torsinA and DAT71 as well
as vesicle monoamine transporter 2 (VMAT2).111
Recent work using more sensitive voltammetry to
measure extracellular DA, however, found evidence to
suggest that it was release not reuptake that was
impaired, arguing against DAT dysfunction.107,112
Further evidence for involvement of presynaptic
vesicles comes from cellular studies. It has been
detected that torsinA is associated with vesicles in
axons and presynaptic terminals, and biochemical
fractionation analysis showed enrichment of torsinA
in the fraction containing synaptosomal mem-
branes.113 TorsinA has also been found to colocalize
with snapin (SNARE-associated protein) on dense-core
granules at the tips of differentiated PC12 cells.114
Functional analysis of SH-SY5Y cells expressing wild-
type or mutant torsinA has shown that it regulates the
degradation of snapin and stonin-2 (synaptotagmin
specific endocytic adapter) by the proteosome, with
mutant torsinA leading to reduced levels and compro-
mised synaptic vesicle recycling.115
Abnormalities in synaptic vesicle recycling has been
supported by recent work in cultured hippocampal
neurons from a knock-in mouse model of DYT1 dys-
tonia that suggested that torsinA regulates recycling at
a level at or upstream of the rise in calcium concentra-
tion in nerve terminals and that the regulation is influ-
enced by neuronal activity.116 Furthermore, using
patch-clamp electrophysiology, it was found that neu-
rons with mutant torsinA had more frequent miniature
glutamate release, which may underlie the excitability
of the CNS in DYT1 dystonia.117 The authors have
not looked at other neurons, potentially more relevant
to basal ganglia dysfunction.
Postsynaptic defects in hMT-CMV-derived striatal sli-
ces showed that activation of D2 receptors (D2Rs) led
to abnormal activation and inappropriate firing of cho-
linergic interneurons118 and GABAergic medium spiny
neurons.119 In addition, medium spiny neurons from
hMT-CMV mice had decreased expression of surface
D2Rs with impaired G-protein coupling, despite nor-
mal levels of D2R mRNA.120 It was suggested that
there was a posttranslational defect in receptor process-
ing. This may occur in the ER for TA, where it acts as
a molecular chaperone, leading to abnormal folding or
oligomerization of the D2R, and a direct interaction
between TA and the D2R has previously been demon-
strated.71 In support of this hypothesis are data from
[11C]-raclopride PET studies that showed reduced levels
of D2R binding in patients with DYT1 and DYT6 dys-
tonia, suggesting a pathogenetic link between these 2
forms and a D2R defect.121,122 For DYT1, reductions
in radioligand binding were found in the caudate, puta-
men, and ventrolateral thalamus.123 Further work
needs to be performed to clarify this area, not least is
whether the potential D2R defect in DYT6 dystonia is
also at a posttranslational level or relates to disrupted
transcription.
The abnormal synaptic plasticity in transgenic mod-
els of primary dystonia has been reviewed recently
and highlighted disruption of synaptic scaling, with
facilitation of synaptic potentiation, together with loss
of synaptic inhibitory processes.124 In the hMT-CMV
model described above, impaired D2R postsynaptic
function was suggested by the inability of the D2R
agonist to reestablish normal corticostriatal synaptic
plasticity. Interestingly, blockade of A2A receptors
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fully restored the impairment of synaptic plasticity.
A2A receptors and D2 receptors oppose each other in
the induction of bidirectional synaptic plasticity, with
D2Rs promoting long-term depression and A2A recep-
tors favoring induction of long-term potentiation. The
effect of the A2AR antagonist suggests the deficit in
D2R function in the model can be reversed by elimi-
nating the negative tone exerted by A2ARs on this.
The possible role of A2ARs in genetic dystonia is also
implicated from preliminary work on GNAL.
GNAL
G-proteins link seven-transmembrane-domain recep-
tors to downstream effectors and function as hetero-
trimers composed of a, b and g subunits. Evidence
suggests that Ga(olf) acts in medium spiny neurons to
couple dopamine type 1 receptors (D1Rs) of the direct
pathway and adenosine A2A receptors (A2ARs) of the
indirect pathway to the activation of adenylate cyclase
type 5.125 A2ARs and Gaolf are also expressed in
striatal cholinergic interneurons. The mutations identi-
fied in GNAL appear to lead to loss of function and
implicate abnormalities in D1R and/or A2AR trans-
mission in the pathogenesis of dystonia.
DYT12: Alpha-3 Subunit of Na1/K1 ATPase
Neuronal dysfunction leading to abnormal neuro-
physiology has been implicated for the DYT12 pro-
tein, alpha-3 subunit of the Na1/K1 ATPase, which
belongs to the group of P-type ATPases, which utilize
energy liberated during the hydrolysis of ATP for
active transport of cations across cell membranes. Bio-
chemical enzyme assays have revealed that mutations
in a3 cause a reduction in both Na1 affinity and
extrusion of intracellular Na1, leading to disrupted
electrochemical ionic gradients across the neuronal
FIG. 3. Schematic diagram of synapse indicating potential impact of proteins whose mutant forms cause dystonia. A: Presynaptic terminal showing
interaction of torsinA, DAT, and mutations in GCH1 and TH on synaptic vesicle recycling, dopamine uptake, and synthesis, respectively. B: Postsy-
naptic terminal. TorsinA and THAP1 may affect dopamine receptor expression of function. D2R and A2AR function may be influenced by these pro-
teins or directly by GNAL influencing PKA phosphorylation and promoting delivery of GluA1-containing AMPARs to extrasynaptic pools, increasing
their availability for subsequent synaptic recruitment on LTP induction and NMDAR activation. Calcium influx through synaptic NMDARs is endoge-
nously facilitated by A2AR, but it can also be inhibited by activation of D2R through PKA-dependent mechanisms. a,b,c, subunits of G protein; DA,
dopamine; D2, dopamine type 2 receptor; D1, dopamine type 1 receptor; GCH1, GTP-cyclohydrolase 1; GNAL, stimulatory a subunit of G protein;
TH, tyrosine hydroxylase, ER, endoplasmic reticulum; A2AR, adenosine 2 receptor; AMPAR, AMPA receptor; NMDAR, NMDA receptor.
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cell membrane.126 It is possible that this may lead to
downstream abnormalities of synaptic function. A
phenotypic model of RDP was recently generated by
chemically inhibiting the a3 isoform of the ATPase
function in selected brain regions using the targeted
infusion of ouabain, which selectively reduces
a3-ATPase function in a dose-dependent manner in ge-
netically wild-type mice.127 Ouabain infusions in the
basal ganglia and cerebellum induced a parkinsonism-
like or dystonic-like phenotype, respectively, but only
concomitant infusions in both structures yielded a
stress-inducible phenotype resembling features of RDP.
In the mouse model, dystonic postures were reduced
following transient inhibition of cerebellar input by
GABA injection, again underlining the emerging impor-
tance of cerebellar dysfunction in dystonia and RDP.
Further evidence to support a dopaminergic etiology
for dystonia comes from the study of dopamine trans-
porter deficiency syndrome.
Dopamine Transporter Deficiency Syndrome
Dopamine transporter deficiency syndrome is an
autosomal recessive condition caused by loss-of-func-
tion mutations in the DAT gene.128,129 DAT is a
transmembrane protein exclusively expressed in dopa-
minergic neurons, in which it mediates the reuptake of
dopamine into presynaptic terminals after synaptic
transmission. This rapid recycling of neurotransmitter
is crucial to synaptic function, as it replenishes dopa-
mine stores in the presynaptic terminal and prevents
desensitization of the postsynaptic terminal. Children
presented in infancy with either hyperkinesia, parkin-
sonism, or a mixed hyperkinetic and hypokinetic
movement disorder. Some individuals had previously
been misdiagnosed with cerebral palsy. During child-
hood they developed severe dystonia-parkinsonism
associated with an eye movement disorder and pyram-
idal tract features. Investigations revealed raised ratios
of homovanillic acid to 5-hydroxyindoleacetic acid in
cerebrospinal fluid. DAT SCAN imaging in 1 patient
showed complete loss of dopamine transporter activity
in the basal nuclei, although a trial of L-dopa had no
effect on either the patient’s symptoms or CSF
parameters.
Common Themes in Dystonia Molecular
Pathways
The increasing knowledge of proteins whose mutant
forms cause dystonia has implicated a large number of
neurobiological pathways that lead to dystonic move-
ments. A number of themes have emerged that have
been identified in this review—from abnormal tran-
scription and cell cycle because of the nuclear effects
of dystonia genes to ER dysfunction and synaptic
abnormalities. It is right to seek common pathways
that may represent targets for therapeutic strategies
for this group of incurable movement disorders. How-
ever, it may also lead to oversimplification in the
search for unifying mechanisms. Most cases of dysto-
nia are primary and not associated with neuronal
death. Thus, the pathogenic mechanisms may be
subtle and only cause relatively mild defects in the rel-
evant pathways, leading to abnormal processing of the
motor command within the CNS.70
There is increasing awareness of the role of abnor-
mal inhibition and plasticity affecting sensorimotor
pathways in dystonia.1 This may be a template laid
down in early life, supporting the view that primary
dystonia is a neurodevelopmental circuit disorder. In
support of this are the developmental patterns of
expression of the best-studied primary dystonia gene
products: torsinA and THAP1. TorsinA expression in
the mouse was highest during prenatal and early post-
natal development, particularly in the cortex, striatum,
thalamus, and cerebellum.130 In the human brain, tor-
sinA protein is detectable at 4–8 weeks postnatally in
the cerebellum (Purkinje cells), substantia nigra hippo-
campus, and basal ganglia.131 Similarly, THAP1 is
expressed in the rat in early development, particularly
in the cerebellum (Purkinje cells), cortical pyramidal
neurons, relay neurons in the thalamus, medium and
cholinergic striatal neurons, dopaminergic substantia
nigra neurons, and hippocampal neurons.132 This
developmentally regulated expression of 2 dystonia-
associated proteins suggests a role in terminal regula-
tion and establishment of key circuits involved in
motor control. The themes identified in this review
would have a significant effect on neurodevelopment
in terms of altered transcription of key genes at the
nuclear level, protein processing and trafficking
through the ER, or altered ER stress response in im-
portant periods of neural cell differentiation, through
to abnormal synaptic function affecting neurotrans-
mission or synaptic plasticity. Any or all of the above
mechanisms could lead to abnormal patterns or
responsiveness of sensorimotor circuits, leading to a
susceptibility to developing an abnormal “dystonic
state.”
It may be that with the increasing number of DYT
loci and better understanding of recently identified
genes encoding CIZ1, GNAL, and ANO3, the key cel-
lular pathogenetic mechanisms involved in the genesis
of dystonic movement will become clearer.
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